--- title: "Cerenome (CNSY) news: offering and Nasdaq notice" url: "https://aibio.space/companies/cerenome/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CNSY offering and Nasdaq notice news: Plus Therapeutics (now Cerenome) cancels warrants, signs $50 million Lincoln Park deal. Cerenome, Inc." --- CNSY Cerenome, Inc. NASDAQ · United States # Cerenome (CNSY) news CNSY offering and Nasdaq notice news Debt Financing · 2026-09-10 ## [Cerenome gets up to $20 million royalty-based facility from 3i, LP](https://aibio.space/news/cerenome-gets-up-20-million-royalty-based-facility-3i-lp/) Cerenome, Inc. received initial funding under a senior secured facility of up to $20 million from 3i, LP, with royalty-based repayments. The company says its cash runway now reaches well into 2028. ## Latest Cerenome news 1. 2025-08-26 Listings [Plus Therapeutics (now Cerenome) wins Nasdaq equity nod, more time on $1.00 bid rule](https://aibio.space/news/plus-therapeutics-now-cerenome-wins-nasdaq-equity-nod-more-time-1-00/) Nasdaq confirmed compliance with both the $35 million market value standard and the $2.5 million equity standard. The bid price deadline moves to November 12, 2025. 2. 2025-06-17 Financings [Plus Therapeutics (now Cerenome) cancels warrants, signs $50 million Lincoln Park deal](https://aibio.space/news/plus-therapeutics-now-cerenome-cancels-warrants-signs-50-million/) Investors in a March 2025 private placement agreed to cancel all Series A warrants and cut Series B warrant shares to up to 35,536,380. Lincoln Park may buy up to $50.0 million of stock over 36 months. 3. 2025-05-23 Listings [Plus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form 10-Q](https://aibio.space/news/plus-therapeutics-now-cerenome-gets-nasdaq-deficiency-notice-late-form/) Nasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan by July 21, 2025, and any exception could run until November 17, 2025. 4. 2025-05-15 Distress [Plus Therapeutics (now Cerenome) says first-quarter 10-Q will be late over warrant accounting](https://aibio.space/news/plus-therapeutics-now-cerenome-says-first-quarter-10-q-will-late/) The company filed an NT 10-Q on May 15, 2025. It needs more time to account for warrants from a March 2025 private placement and expects lower stockholders' equity at March 31, 2025. 5. 2025-05-15 Distress [Plus Therapeutics (now Cerenome) delays Q1 report over warrant accounting from March PIPE](https://aibio.space/news/plus-therapeutics-now-cerenome-delays-q1-report-warrant-accounting/) The company needs more time to finalize accounting for common stock purchase warrants issued in its March 2025 private placement. It expects a warrant liability that will lower stockholders' equity. ## Cerenome at a glance - **Ticker**: CNSY - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $8.6 million ### Related companies - [TETRALOGIC PHARMACEUTICALS CORP](https://aibio.space/companies/tetralogic-pharmaceuticals/) OTC: TLOG - [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH - [Petros Pharmaceuticals](https://aibio.space/companies/petros-pharmaceuticals/) OTC: PTPI - [Jupiter Neurosciences](https://aibio.space/companies/jupiter-neurosciences/) NASDAQ: JUNS - [Anebulo Pharmaceuticals](https://aibio.space/companies/anebulo-pharmaceuticals/) OTC: ANEB - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) NASDAQ: IONS - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT ### Also on NASDAQ - [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) KRYS - [Atara Biotherapeutics](https://aibio.space/companies/atara-biotherapeutics/) ATRA - [Jyong Biotech](https://aibio.space/companies/jyong-biotech/) MENS - [Intercure](https://aibio.space/companies/intercure/) INCR - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) MIRM - [Medpace Holdings](https://aibio.space/companies/medpace/) MEDP ## Cerenome annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | | Research and development | [$8.4 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | [$10.6 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | | Net income (loss) | [-$22.4 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | [-$13.0 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | | Cash from operations | [-$20.8 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | [-$10.6 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | | Cash and equivalents | [$4.3 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526352444/) | [$76,000](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | | Short-term investments | [$4.4 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526352444/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1095981/000119312526104258/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.4 million, plus short-term investments of $6.2 million, $8.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cerenome Has Cerenome raised money recently? Our latest story on this, dated Jun 17, 2025: "Plus Therapeutics (now Cerenome) cancels warrants, signs $50 million Lincoln Park deal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/plus-therapeutics-now-cerenome-cancels-warrants-signs-50-million/). Has Cerenome received a Nasdaq deficiency notice? Our latest story on this, dated May 23, 2025: "Plus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form 10-Q". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/plus-therapeutics-now-cerenome-gets-nasdaq-deficiency-notice-late-form/). What is the ticker symbol of Cerenome? Cerenome, Inc. trades under the ticker CNSY on NASDAQ. Where is Cerenome listed? Cerenome, Inc. is listed on NASDAQ. What is the SEC CIK of Cerenome? The SEC Central Index Key (CIK) for Cerenome, Inc. is 1095981. Its filings are on SEC EDGAR. How many shares does Cerenome have outstanding? 7,589,625 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Cerenome listed under? Our directory records Cerenome, Inc. under United States. What does Cerenome do? Our directory classifies Cerenome, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cerenome? The ISIN recorded for Cerenome, Inc. is US72941H8060. Does aibio.space cover Cerenome? aibio.space lists Cerenome, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cerenome incorporated? SEC records list its state or country of incorporation as DE. What was Cerenome's revenue last year? $5.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Cerenome profitable? Cerenome, Inc. reported a net loss of $22.4 million for the fiscal year ended Dec 31, 2025, and used $20.8 million of cash in operations, per its annual report to the SEC. How much does Cerenome spend on research and development? $8.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Cerenome have? $8.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Cerenome Members talk about Cerenome (CNSY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cerenome, newest first. Each line links the filing it comes from. 1. 2026-09-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312526387267/d382364dex991.htm) 2. 2026-06-02 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312526252119/d138711ds3.htm) 3. 2026-05-15 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/pstv-20260514.htm) 4. 2026-04-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312526165205/pstv-ex99_1.htm) 5. 2026-04-02 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312526140267/pstv-ex99_1.htm) 6. 2026-01-09 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312526008922/d12907ds1.htm) 7. 2025-11-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525283935/d55484dex991.htm) 8. 2025-08-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525188075/d919644d8k.htm) 9. 2025-08-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525179382/d930191d8k.htm) 10. 2025-08-12 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525179012/d71976d8k.htm) 11. 2025-07-21 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1095981/000114036125026611/ny20044912x2_def14a.htm) 12. 2025-07-18 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525161239/d45208d8k.htm) 13. 2025-07-11 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1095981/000114036125025650/ny20044912x1_pre14a.htm) 14. 2025-06-17 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525142093/d942989d8k.htm) 15. 2025-06-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525137089/d39292d8k.htm) 16. 2025-05-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525125860/d947753dex991.htm) 17. 2025-05-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000095017025074374/pstv-20250516.htm) 18. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1095981/000095017025072596/plus_q1_2025_nt.htm) 19. 2025-05-02 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000095017025062742/pstv-20250502.htm) 20. 2025-04-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1095981/000114036125013256/ny20044910x3_def14a.htm) 21. 2025-03-14 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1095981/000114036125008857/ny20044910x1_pre14a.htm) 22. 2025-03-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525050390/d938890d8k.htm) 23. 2025-03-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312525045305/d875007d8k.htm) 24. 2024-11-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1095981/000119312524249270/d860547d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CNSY on TradingView](https://www.tradingview.com/symbols/NASDAQ-CNSY/). ## SEC filings and registration - **SEC name**: Cerenome, Inc. - **CIK**: 1095981 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: CNSY (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 6420 LEVIT GREEN BOULEVARD, HOUSTON, TX, 77021 - **Phone**: 737.255.7194 - **Shares outstanding**: 7,589,625 as of 2026-08-05 (10-Q filed 2026-08-14) - **Former names**: PLUS THERAPEUTICS, INC.; CYTORI THERAPEUTICS, INC.; MACROPORE INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1095981/000119312526411259/cnsy-20261002.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1095981/000119312526387267/d382364d8k.htm) filed 2026-09-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1095981/000119312526352444/pstv-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1095981/000119312526352346/pstv-20260814.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1095981/000119312526332939/pstv-20260803.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1095981/000119312526259703/pstv-20260601.htm) filed 2026-06-05 - [S-3](https://www.sec.gov/Archives/edgar/data/1095981/000119312526252119/d138711ds3.htm) filed 2026-06-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/pstv-20260514.htm) filed 2026-05-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001095981), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cerenome, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CNSY, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cerenome, Inc. - **Ticker**: CNSY - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US72941H8060 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CNSY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cerenome/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cerenome (CNSY) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/cerenome/